VTGN VistaGen Therapeutics
- 4.7400
- -0.0900-1.86%
VistaGen Therapeutics News
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
Express News | Vistagen Therapeutics Inc: Ph15 Was Safe and Well-Tolerated With an Adverse Event Profile Similar to Placebo
Express News | Vistagen Therapeutics Inc: Ph15 Nasal Spray Demonstrates Statistically Significant Efficacy Versus Placebo and Caffeine
Express News | Vistagen Announces Positive Results From Phase 2a Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Vistagen Announces Positive Results From Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants.
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced
30 Countries With the Lowest Depression Rates
This Overlooked Corner of Women's Health Could Be a $350 Billion Market Opportunity
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
Vistagen to Present at Stifel 2024 Virtual CNS Days
Vistagen (NASDAQ:VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
Vistagen (NASDAQ:VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management
10 Health Care Stocks Whale Activity In Today's Session
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth.
Earnings Call: Vistagen Reports on Clinical Updates and Financial Health
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q3 2024 Earnings Conference
The following is a summary of the Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript:Financial Performance:VistaGen reported a net loss of $6.3 million in Q3 2024, improving from the
Vistagen Therapeutics Files for $350M Mixed Shelf
VistaGen Therapeutics Q3 EPS $(0.22) Beats $(0.30) Estimate, Sales $411.40K Miss $544.50K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.30) by 26.67 percent. This is a 84.51 percent increase over losses o
Recap: Vistagen Therapeutics Q3 Earnings
Vistagen Therapeutics (NASDAQ:VTGN) reported its Q3 earnings results on Tuesday, February 13, 2024 at 04:21 PM.Here's what investors need to know about the announcement.EarningsVistagen Therapeutics b
VistaGen Therapeutics 3Q Loss/Shr 22c >VTGN
VistaGen Therapeutics 3Q Loss/Shr 22c >VTGN
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. • Navios Maritime Partners (NYSE:NMM) is projected
Notable Earnings After Tuesday's Close
VistaGen Therapeutics's Earnings: A Preview
VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Tuesday, 2024-02-13. Here's what investors need to know before the announcement.Analysts estimate that VistaG
Analysis
Price Target
No Data
